Scientific Sessions 2024  /  Epigenomics, RNA Networks, and Cell Plasticity in Pulmonary Hypertension: New Biomarkers and Therapeutic Targets?  /  Targeting Epigenetic Modifications is a Viable Disease Modifying Strategy for Patients with Pulmonary Hypertension: The Pros and Cons
Logo

American Heart Association

  129
  0

Final ID:

Targeting Epigenetic Modifications is a Viable Disease Modifying Strategy for Patients with Pulmonary Hypertension: The Pros and Cons

  • Savai Pullamsetti, Soni  ( Max-Planck-Institute for Heart and Lung Research, Department of Lung Development and Remodeling , Bad Nauheim , Germany )
  • Michelakis, Evangelos  ( University of Alberta , Edmonton , Alberta , Canada )
    • Author Disclosures:
    Soni Savai Pullamsetti: DO NOT have relevant financial relationships | Evangelos Michelakis: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Epigenomics, RNA Networks, and Cell Plasticity in Pulmonary Hypertension: New Biomarkers and Therapeutic Targets?

Monday, 11/18/2024 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Epigenetic Age in Pulmonary Hypertension: Is it Relevant?

Potus Francois, Rhodes Christopher

Epigenetic Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Hypertension

Hadri Lahouaria, Stenmark Kurt, Goncharova Elena, Bonnet Sebastien

More abstracts from these authors:
Mitochondrial Dysfunction in PAH: A Targetable Vulnerability?

Rafikov Ruslan, Michelakis Evangelos, Archer Stephen

Lipid Metabolism in PAH: A Driver of Vascular Dysfunction?

Chan Stephen, Michelakis Evangelos, Brittain Evan

You have to be authorized to contact abstract author. Please, Login
Not Available